. 2021 Mar 6;11(3):456. doi: 10.3390/diagnostics11030456

Table 1.

Clinical characteristics of the enrolled idiopathic nephrotic syndrome (INS) patients.

Patient ID	Sex	Age * (Years)	uPr/uCr (mg/mg)	Ongoing Therapy (Months) ^§
Patient ID	Sex	Age * (Years)	uPr/uCr (mg/mg)	PRED	CYCL	MMF	TACR
SSNS
16	M	5	0.13	2
21	M	3	1.67
24	M	4	0.27	1
43	M	17	0.08
44	F	16	0.13
67	F	11	0.16
73	M	10	0.12	1
74	M	11	0.12	<1
SDNS
5	M	5	0.24	<1		33	3
6	M	10	0.14			15
7	M	12	0.60	2		96
8	M	5	0.23			26	6
9	M	7 (I)	0.18			26
		+4 months (II)	0.18			30
		+10 months (III)	0.18			36
10	M	18	0.08			5
13	F	4	0.19			29
14	F	8	0.18			8
18	M	8	0.15			28
20	M	5 (I)	0.17			38
20	M	+10 months (II)	0.13			48
23	F	2 (I)	0.34			5
23	F	+5 months (II)	0.30			10
30	F	6	0.16			1
32	F	8	0.15	2		1
38	M	15	0.27	<1		<1
53	M	10	0.84			49
55	M	5	0.74		38	39
58	M	12	0.15		32
61	M	7	0.25			14
66	F	6	0.14			30
69	F	15	0.15			130
SRNS
11	F	14	0.10		33	32
12	F	8	0.11		33
17	M	14 (I)	0.44	17			6
17	M	+8 months (II)	0.32				14
39	F	12	0.14		<1
70	F	11	0.13

*, age at the time of urine collection; ^§, months of therapy at the time of urine collection; SDNS, corticosteroid-dependent; SSNS, corticosteroid-sensitive; SRNS, corticosteroid-resistant; PRED, prednisone; CYCL, cyclosporin; MMF, mycophenolate mofetil; TACR, tacrolimus; OP, orthostatic proteinuria; uPr, urinary proteins; uCr, urinary creatinine; M, male; F, female; I, first collection; II, second collection; III, third collection.